Innoviva Share Holder Equity 2010-2024 | INVA

Innoviva share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Innoviva Annual Share Holder Equity
(Millions of US $)
2023 $675
2022 $566
2021 $526
2020 $608
2019 $342
2018 $159
2017 $-243
2016 $-353
2015 $-343
2014 $-223
2013 $299
2012 $155
2011 $-87
2010 $-22
2009 $-189
Innoviva Quarterly Share Holder Equity
(Millions of US $)
2024-03-31 $704
2023-12-31 $675
2023-09-30 $627
2023-06-30 $555
2023-03-31 $561
2022-12-31 $566
2022-09-30 $641
2022-06-30 $565
2022-03-31 $552
2021-12-31 $526
2021-09-30 $492
2021-06-30 $394
2021-03-31 $697
2020-12-31 $608
2020-09-30 $535
2020-06-30 $493
2020-03-31 $406
2019-12-31 $342
2019-09-30 $284
2019-06-30 $247
2019-03-31 $200
2018-12-31 $159
2018-09-30 $-108
2018-06-30 $-155
2018-03-31 $-213
2017-12-31 $-243
2017-09-30 $-223
2017-06-30 $-297
2017-03-31 $-334
2016-12-31 $-353
2016-09-30 $-368
2016-06-30 $-363
2016-03-31 $-362
2015-12-31 $-343
2015-09-30 $-323
2015-06-30 $-294
2015-03-31 $-260
2014-12-31 $-223
2014-09-30 $-193
2014-06-30 $-188
2014-03-31 $263
2013-12-31 $299
2013-09-30 $330
2013-06-30 $86
2013-03-31 $92
2012-12-31 $155
2012-09-30 $173
2012-06-30 $189
2012-03-31 $6
2011-12-31 $-87
2011-09-30 $-59
2011-06-30 $-37
2011-03-31 $-28
2010-12-31 $-22
2010-09-30 $-141
2010-06-30 $-126
2010-03-31 $-113
2009-12-31 $-189
2009-09-30 $-175
2009-06-30 $-159
2009-03-31 $-144
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.013B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27